Abbott (NYSE:ABT) announced today that it entered into a definitive agreement to acquire smart insulin management company Bigfoot Biomedical. The transaction remains subject to customary closing conditions and the companies declined to disclose financial terms. They expect it to close in the third quarter of 2023. Abbott has a longstanding relationship with Bigfoot going back […]
GLP-1 startup i2o looks to revive diabetes drug-eluting implant from Intarcia
i2o Therapeutics says it acquired the diabetes-treating assets of one-time medtech unicorn Intarcia Therapeutics. The Boston-based company acquired and integrated Intarcia’s proprietary assets and made a big personnel move. With CEO Ravi Srinivasan moving onto other opportunities, i2o named Kurt Graves as chair, president and CEO. Graves previously served as executive chair of the i2o […]
Lawsuit alleges ‘potentially problematic’ patient data sharing from Medtronic Diabetes devices
A class-action lawsuit filed against Medtronic (NYSE:MDT) alleges that the company’s insulin delivery devices shared patient data with third parties. The lawsuit — filed by the plaintiff “A.H.” in U.S. District Court in Central California — levels allegations against Medtronic and its MiniMed and InPen devices. It addresses MiniMed’s transmission and disclosure of personally identifiable information […]
Glucotrack tabs former Medtronic veteran for a board director spot
Glucotrack (Nasdaq:GCTK) announced today that it appointed Erin Carter to its board of directors, naming her chair of its audit committee. Carter’s appointment comes just days after the implantable continuous glucose monitor (CGM) maker named Drinda Benjamin VP of marketing. She becomes a member of the board and chair of the audit committee, effective immediately. “We […]
Beta Bionics closes $100M Series D to support bionic pancreas
Beta Bionics announced that it successfully closed a Series D funding round, securing $100 million in new equity capital. Concord, Massachusetts-based Beta Bionics develops its flagship iLet bionic pancreas. The autonomous insulin delivery system streamlines diabetes management and reduces the burden on patients and physicians. iLet received FDA clearance in May. While Beta Bionics did […]
Emergent BioSolutions launches over-the-counter Narcan nasal spray
Emergent BioSolutions (NSYE:EBS) announced today that it plans to put its over-the-counter Narcan nasal spray on U.S. shelves next month. FDA approved the over-the-counter Narcan spray in May. Approval enabled direct-to-consumer sales in places like drug stores, convenience stores and more. The FDA nod came about six weeks after an agency committee voted unanimously in favor […]
Implantable CGM maker Glucotrack names new VP of marketing
Glucotrack (Nasdaq:GCTK) announced that it appointed Drinda Benjamin as its new vice president of marketing. Rutherford, New Jersey-based Glucotrack develops an implantable continuous glucose monitor (CGM). It designed its CGM for patients with type 1 and type 2 insulin-dependent diabetes. A recent feasibility study demonstrated reliable glucose measurements for two years post-implant for the device. […]
FDA clears new infusion pump and software from ICU Medical
ICU Medical (Nasdaq:ICUI) announced today that the FDA granted 510(k) clearance to its Plum Duo infusion pump with LifeShield infusion safety software. The San Clemente, California-based company plans to make the pump and software available to U.S. customers in early 2024. Plum Duo, the latest addition to the ICU Medical infusion device portfolio, builds on […]
Dexcom appoints a new board director
Dexcom (Nasdaq:DXCM) announced today that it appointed Rimma Driscoll to its board of directors. The San Diego-based continuous glucose monitor (CGM) maker made Driscoll’s appointment effective on Aug. 24. She currently serves as EVP and head of global strategy, commercial and business development and global biodevices for Zoetis. At Zoetis, a leading animal health company […]
Insulet fully launches Omnipod 5 in Germany, expects full European availability by end of 2024
Insulet (Nasdaq:PODD) announced today that it commercially launched its Omnipod 5 automated insulin delivery system in Germany. Acton, Massachusetts-based Insulet released the device for individuals aged two years and older with type 1 diabetes. Germany marks the third market for the latest-generation patch pump. The company launched Omnipod 5 in the U.S. in August 2022, […]